Dr. Stratton on phase 1B trial of relugolix and enzalutamide in high-risk prostate cancer

Opinion
Video

"Unique to this study is that we'll be using Orgovyx," says Kelly L. Stratton, MD, FACS.

In this video, Kelly L. Stratton, MD, FACS, gives an overview of a phase 1B trial evaluating relugolix (Orgovyx) and enzalutamide (Xtandi) for high-risk prostate cancer. Stratton is an associate professor of urologic oncology at the University of Oklahoma, Oklahoma City.

Transcription:

Please provide an overview of this study.

This is a study of relugolix and enzalutamide in patients with locally advanced prostate cancer. These are high-risk patients who have high-grade cancer. Some of them may have pelvic lymph node disease, and we're looking at combined hormonal therapy, before radiation or surgery, and then also additional treatment after, again, either radiation or surgery. The rationale is that these patients are at very high risk for recurrence and the development of metastatic disease. We understand the activity of combined hormonal therapy, and our hope is that by adding combined hormonal therapy, both before and after local treatment, we can improve our outcomes for these patients. Unique to this study is that we'll be using Orgovyx, which is an oral drug that is a testosterone-reducing drug, an LHRH antagonist. That medicine works to lower the testosterone and different than what we typically use—leuprolide—it may have some potential benefits from the perspective that it may have less cardiac risks, it also works faster, and when you're done taking it, it stops working faster as well, so it doesn't linger as long as leuprolide would. Patients will receive 2 years of combined hormonal therapy in this study, and we'll be looking at the pathologic complete response rate in patients undergoing surgery, minimal disease rate in patients undergoing surgery, and then also objective response rate and patients either undergoing surgery or radiation.

This transcription was edited for clarity.

Related Videos
Marc Bjurlin, DO, MSc, FACOS, answers a question during a Zoom video interview
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
John Michael DiBianco, MD, answers a question during a Zoom video interview
Shaya Taghechian, MD, answers a question during a video interview
Human kidney cross section on science background | Image Credit: © Crystal light - stock.adobe.com
A panel of 4 experts on prostate cancer
Joseph Song, MD, answers a question during a video interview
© 2024 MJH Life Sciences

All rights reserved.